Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?

Simply Wall St.06:19

Bristol-Myers Squibb (BMY) just received expanded FDA approval for CAMZYOS in symptomatic obstructive hypertrophic cardiomyopathy, now including eligible pediatric patients. This development sharpens ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2673163069?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/25798-card/1789118977455","is_english":true,"pubTime":"2026-10-07 06:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2673163069","market":"sg","top_or_hot":-1,"title":"Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?","media":"Simply Wall St.","content":"<div>\n<p>Bristol-Myers Squibb (BMY) just received expanded FDA approval for CAMZYOS in symptomatic obstructive hypertrophic cardiomyopathy, now including eligible pediatric patients. This development sharpens ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-expands-camzyos-approval-is-the-sto\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-07 06:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-expands-camzyos-approval-is-the-sto><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol-Myers Squibb (BMY) just received expanded FDA approval for CAMZYOS in symptomatic obstructive hypertrophic cardiomyopathy, now including eligible pediatric patients. This development sharpens ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-expands-camzyos-approval-is-the-sto\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1718418525.SGD","symbol_name":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-expands-camzyos-approval-is-the-sto","article_id":"2673163069","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/25798-card/1789118977455"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-expands-camzyos-approval-is-the-sto","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2673163069","pubTimestamp":1791325173,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Bristol-Myers Squibb (BMY) just received expanded FDA approval for CAMZYOS in symptomatic obstructive hypertrophic cardiomyopathy, now including eligible pediatric patients. This development sharpens the focus on how this cardiac franchise feeds into the broader equity story.\nCAMZYOS’ broader label arrives after a mixed stretch for Bristol-Myers Squibb’s stock, with a 1-day share price return of 1.33% following the news, a 7-day share price decline of 5.20%, and a 30-day share price drop of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2596442595.SGD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (SGDHDG) INC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BMY":"施贵宝","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4532":"文艺复兴科技持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IHE":"iShares U.S. Pharmaceuticals ETF","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BK4585":"ETF&股票定投概念","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0237698245.USD":"富达环球地产基金A"},"translate_title":"百时美施贵宝 (BMY) 扩大 CAMZYOS 批准，该股还便宜吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IHE":0.6,"BMY":1.5,"FTXH":0.6},"content_text":"Bristol-Myers Squibb (BMY) just received expanded FDA approval for CAMZYOS in symptomatic obstructive hypertrophic cardiomyopathy, now including eligible pediatric patients. This development sharpens the focus on how this cardiac franchise feeds into the broader equity story. CAMZYOS’ broader label arrives after a mixed stretch for Bristol-Myers Squibb’s stock, with a 1-day share price return of 1.33% following the news, a 7-day share price decline of 5.20%, and a 30-day share price drop of 10.82%. This contrasts with an 11.47% year-to-date share price gain and a 39.37% total shareholder return over the past year, which together indicate that longer term momentum has been building even as short term sentiment has cooled and investors reassess risk and growth potential across the pipeline. Spot 27 high quality undervalued stocks that, like Bristol-Myers Squibb after the CAMZYOS approval, pair established franchises with fresh clinical catalysts that could reshape market expectations.\nBristol-Myers Squibb now trades at US$59.59, while analyst targets cluster nearer US$66 and some intrinsic value models point much higher. Where does a reasonable view of fair value actually land after this move? AdvertisementMost Popular Narrative: 10.7% Undervalued Bristol-Myers Squibb’s most followed valuation narrative pegs fair value at about $66.71, which sits above the latest close at $59.59 and frames today’s discount as modest rather than extreme.  Ongoing shift in Bristol-Myers Squibb’s revenue mix toward its growth portfolio, which reached $7.6b in Q2 2026 and nearly 60% of total sales, supports the view that new products can increasingly offset legacy erosion and underpin future revenue and earnings.  See why 228 investors see Bristol-Myers Squibb as 11% undervalued. Result: Fair Value of $66.71 (UNDERVALUED) Still, Bristol-Myers Squibb faces two clear pressure points: faster than expected erosion after major patent expiries and any further safety or delay issues across key late stage programs. Find out about the key risks to this Bristol-Myers Squibb narrative. Next Steps Mixed signals on Bristol-Myers Squibb’s outlook can be confusing, so consider acting promptly, review the full risk and reward stack, and shape your own stance with 4 key rewards and 3 important warning signs Looking for more Bristol-Myers Squibb style investment ideas? If you are serious about sharpening your portfolio after the Bristol-Myers Squibb news, use focused screeners to surface candidates that match your risk and income goals.  Target sturdier balance sheets by reviewing companies in the list of solid balance sheet and fundamentals (25 results) that can potentially handle setbacks without constant refinancing pressure. Hunt for potential mispricings through the 27 high quality undervalued stocks and avoid leaving possible value opportunities sitting on the sidelines. Build a steadier income base by scanning the 8 dividend fortresses and stress testing which payouts might hold up when conditions turn tougher.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bristol-Myers Squibb might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2673163069","isCrawlerRequest":true}